Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Investment
Merck signs discovery pact with Curve Therapeutics
by Michael McCoy
February 20, 2022
| A version of this story appeared in
Volume 100, Issue 7
Merck & Co. will pay Curve Therapeutics an undisclosed sum to discover modulators of up to five oncology and neurology targets using its Microcycle technology. Curve is a 2019 spin-off from Ali Tavassoli’s chemistry lab at the University of Southampton. The firm screens hexameric cyclic peptides against therapeutic targets in the cytoplasm of mammalian cells. The firm says its peptides are small enough to be transformed into nonpeptidic small molecules that can be further developed into drugs.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter